

CAP TODAY

WHERE THE WORLD OF THE CLINICAL LABORATORY COMES TOGETHER

For more information and availability contact:

West: Lori Prochaska | 402-290-7670 | lori@captoday.org
Midwest: Alex Pacheco | 402-290-8203 | alex@captoday.org
East: Lori Prochaska and Alex Pacheco | lori@captoday.org and alex@captoday.org
Sales and Support: Nicole Quackenbush | 402-960-2869 | nicole@captoday.org

eDirects | Branded Message

Reach 50,000 lab professionals with your message.

Your branded e-blast goes directly to pathologists, lab directors, technologists, and hospital administrators from the CAP database.

Options:

- \$4,500 per blast
- \$4,300 6 or more per year
- \$4,100 12 or more per year

Reblast add-on option:

Maximize your campaign's reach with the opportunity to reblast your custom message and recapture readers' attention while increasing engagement. Reblasts are sent within 7 days of your initial email to recipients who did not open or did not click your content. **\$1,500**

EDIRECTS | BRANDED MESSAGE

Discover the Oncomine Comprehensive Assay Plus on the Genexus System [Explore now](#)

The Ion Torrent™ Oncomine™ Comprehensive Assay Plus on the Ion Torrent™ Genexus™ System is a complete, end-to-end comprehensive genomic profiling (CGP) solution that detects a broad range of genomic alterations from 517 genes, including single-nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), and fusions. Additionally, the assay detects genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI).

Requiring as little as 20 minutes of hands-on time with two touchpoints, Ion Torrent™ technology and highly automated systems allow the reporting of CGP results as soon as the next day to support important insights in a timely manner. As a single vendor of sample-to-report solutions, including instruments, consumables, analysis, and support, Thermo Fisher Scientific helps simplify bringing in-house CGP to your laboratory regardless of your level of next-generation sequencing (NGS) experience.

The Genexus System

Instrumentation

Moving the needle on fentanyl-related overdoses

Fentanyl exposure continues to rise in the U.S., yet the percentage of labs testing for fentanyl is low, at only about 5%. **Laboratory testing indicates 7 out of every 10 pills seized by DEA contain a lethal dose of fentanyl.** Monitoring trends in fentanyl exposure coupled with legislative testing mandates can help implement appropriate harm reduction strategies to minimize the risk of fentanyl overdose across the U.S.

A new white paper explores a multi-faceted approach to combatting fentanyl-related deaths and minimizing the risk of overdose nationwide.

Key strategies highlighted in the white paper include:

- Monitoring overdose rates due to illicit drug use
- Drug screening to identify fentanyl contamination
- Surveillance of fatal and nonfatal fentanyl overdoses
- Implementing harm reduction interventions and potential partnership opportunities

[Download the white paper](#)

¹ <https://www.dea.gov/onepill>

Whitepaper Download

Visit Tosoh at ADLM!

New and Proven Solutions for Immunoassay and HPLC HbA1c Testing

ADLM Booth #331

[READ MORE](#)

Tosoh Bioscience ADLM 2025

Tosoh Launches Our First Ever Speaker Series at ADLM!

At ADLM (booth #331) in Chicago, Tosoh will host a full line-up of industry experts to speak live on clinical diagnostic, educational and technology topics. Stop by our booth for the schedule.

[Tosoh ADLM Speaker Schedule](#)

Can't Attend?
Register now to receive the on-demand versions of the talks when available.

[Register!](#)

Tosoh Immunoassay and HbA1c Analyzers are built for precision and speed, allowing laboratories to perform complex testing quickly with high levels of accuracy.

Next Generation Systems for A1c and Immunoassay

The GR01 HPLC A1c Analyzer is Tosoh's next generation small footprint/high throughput solution for A1c testing using ion-exchange HPLC with variant detection. *GR01 is pending 510(k) clearance.*

The AIA®-CL Series of Chemiluminescent Enzyme Immunoassay Analyzers are fully automated diagnostic solutions that offer a spectrum of advanced features and benefits. *AIA-CL Series, including AIA-CL300, is being prepared for FDA submission.*

email: info.diag.am@tosoh.com
 address: 3600 Gantz Road, Grove City, OH 43123

TOSOH BIOSCIENCE

Conference Preview



Cardiac Advance Controls Detect Troponin with Greater Sensitivity **BIO-RAD**

Test for Troponin Confidently with Cardiac Advance Controls


Try Bio-Rad's latest cardiac assessment control with optimized high-sensitivity troponin ranges, Cardiac Advance!

When testing at low levels of troponin, being confident in your results is difficult. Our new control improves on Cardiac Markers Plus LT to detect troponin even near the limit of detection.

Discover a new level of efficiency and performance with Cardiac Advance Controls, now with 10 highly tested cardiac analytes!

Enhance Your Cardiac Testing

Detect Troponin With Greater Sensitivity



Cardiac Advance has highly optimized high sensitivity troponin targets near the limit of detection. That means you can be more confident in test results with lower concentrations of troponin, allowing for faster assessment of patient outcomes.

Adhere to AACC and IFCC Regulatory Guidelines

New Product Launch

Unlocking Deeper Insights: HER2 in Breast Cancer with Digital Pathology

Roche invites you to join us for the "Unlocking Deeper Insights: HER2 in Breast Cancer with Digital Pathology" webinar.

Learning Objectives:

- Comprehensively review the levels of HER2 IHC expression.
- Examine the advantages of incorporating HER2 chromogenic in situ hybridization into the pathology laboratory workflow.
- Review the benefits and utility of AI assistive tools in HER2 scoring and assessment in breast cancer.
- Observe a demonstration of a HER2 scoring workflow incorporating digital and AI tools.

***Key:** Digital Pathology software is intended for specific clinical applications and is for research and educational use for other applications. Please review the product labeling for compliance before utilization. Roche image analysis algorithms are for research use only. Not for use in diagnostic procedures.

Speakers:

Dr. Angela Baldwin MD, MPH, FCAP, FNAME, Pathology Liaison, US Medical and Scientific Affairs, Roche Diagnostics

Dr. Audrey Bennett, MD, FCAP, Pathology Liaison, US Medical and Scientific Affairs, Roche Diagnostics

September 24, 2025 1:00 - 2:00 PM EST

[Register Now](#)

Webinar Promotion